2. Neuronal Signaling Stem Cell/Wnt
  3. Notch
  4. Limantrafin

Limantrafin (CB-103) is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. Limantrafin has anti-tumor activity.

For research use only. We do not sell to patients.

CAS No. : 218457-67-1

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Limantrafin Related Antibodies

Top Publications Citing Use of Products

    Limantrafin purchased from MedChemExpress. Usage Cited in: Reprod Biol Endocrinol. 2026 Jan 28;24(1):30.

    Western blot of the Ho-1 expression in the CP group, the CP + CB103 (Limantrafin) group, and the CP + CB103 + LIPUS group.

    Limantrafin purchased from MedChemExpress. Usage Cited in: Nat Struct Mol Biol. 2024 May 20.  [Abstract]

    The mRNA levels of HES1 and HES4 in A549 cells treated with or without 10 μM CB-103 (Limantrafin) for 24 hours were measured.

    Limantrafin purchased from MedChemExpress. Usage Cited in: Nat Struct Mol Biol. 2024 May 20.  [Abstract]

    The protein levels of HES1 and HES4 in A549 cells treated with or without 10 μM CB-103 (Limantrafin) for 24 hours were measured.

    Limantrafin purchased from MedChemExpress. Usage Cited in: Oncogene. 2023 Aug;42(34):2521-2535.  [Abstract]

    RT-qPCR results showed that CB103 (Limantrafin) inhibited the expression of NOTCH1 and HES1 genes in LPS246 cells.

    Limantrafin purchased from MedChemExpress. Usage Cited in: Oncogene. 2023 Aug;42(34):2521-2535.  [Abstract]

    Representative dose-response curves of LPS246 cells to different concentrations of CB103 (Limantrafin) and their corresponding IC50 values.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Limantrafin (CB-103) is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. Limantrafin has anti-tumor activity[1][2][3][4].

    IC50 & Target

    notch signaling pathway[1]
    In Vitro

    Limantrafin acts as a pan-NOTCH inhibitor by targeting NOTCH transcriptional activation complex[2].
    Limantrafin can block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines[2].
    Limantrafin exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Limantrafin Related Antibodies

    Cell Viability Assay[1]

    Cell Line: RPMI 8402, KOPTK1, PANC1, nRas driven melanoma cells
    Concentration: 10 μM
    Incubation Time: 4 days, 6 days
    Result: Caused a significant reduction in their growth potential.
    In Vivo

    Limantrafin inhibits NOTCH dependent cellular processes in mice[2].
    Limantrafin blocks in vivo growth of PDX models of T-ALL[2].
    Limantrafin (25 mg/kg; i.p./p.o.; 2x daily; for 2 weeks) inhibits growth of GSI/Mab resistant triple negative breast cancer[3].
    Limantrafin exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: NSG mice, triple negative breast cancer mouse xenograft model[3]
    Dosage: 25 mg/kg
    Administration: Oral administration/Intraperitoneal injection; 2x daily; for 2 weeks
    Result: Inhibited growth of GSI/Mab resistant triple negative breast cancer.
    Clinical Trial
    Molecular Weight

    242.32

    Formula

    C15H18N2O
    CAS No.
    Appearance

    Solid

    SMILES

    NC1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)N=C1
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (412.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.1268 mL 20.6339 mL 41.2677 mL
    5 mM 0.8254 mL 4.1268 mL 8.2535 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.97%

    SDS (393 KB)

    COA (244 KB) HNMR (203 KB) RP-HPLC (246 KB) LCMS (104 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.1268 mL 20.6339 mL 41.2677 mL 103.1694 mL
    5 mM 0.8254 mL 4.1268 mL 8.2535 mL 20.6339 mL
    10 mM 0.4127 mL 2.0634 mL 4.1268 mL 10.3169 mL
    15 mM 0.2751 mL 1.3756 mL 2.7512 mL 6.8780 mL
    20 mM 0.2063 mL 1.0317 mL 2.0634 mL 5.1585 mL
    25 mM 0.1651 mL 0.8254 mL 1.6507 mL 4.1268 mL
    30 mM 0.1376 mL 0.6878 mL 1.3756 mL 3.4390 mL
    40 mM 0.1032 mL 0.5158 mL 1.0317 mL 2.5792 mL
    50 mM 0.0825 mL 0.4127 mL 0.8254 mL 2.0634 mL
    60 mM 0.0688 mL 0.3439 mL 0.6878 mL 1.7195 mL
    80 mM 0.0516 mL 0.2579 mL 0.5158 mL 1.2896 mL
    100 mM 0.0413 mL 0.2063 mL 0.4127 mL 1.0317 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Limantrafin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Limantrafin218457-67-1CB-103CB103CB 103NotchnotchsignalingpathwayleukemiaInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Limantrafin
    Cat. No.:
    HY-135145
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.